Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

Table 5 Parameter values that have been specified by locally fitting the vascular tumour growth model to experimental data extracted from [61]

Cell line	Experimental group	λ ₁	c	d	β	p	K ₀	RMSE	FOO
		day⁻¹	mg/day · mm^3p · kg	day⁻¹ · mm⁻²	mm^3p	-	mm³	mm³
H226 (lung cancer cells)	Control	0.1028	0.7264	0.0075	-	-	208.6162	16.7273	2.57 · 10⁻¹
	Treatment 1	0.1028	0.3982	0.0075	1	4.9963	183.4523	22.2226	10⁻³
	(1 mg/kg)	0.1028	0.3982	0.0075	1	4.9963	183.4523	22.2226	10⁻³
	Treatment 2	0.1028	0.3214	0.0075	1	5.6544	118.7044	8.0860	1.12 · 10⁻⁴
	(5 mg/kg)	0.1028	0.3214	0.0075	1	5.6544	118.7044	8.0860	1.12 · 10⁻⁴
	Treatment 3	0.1028	0.1735	0.0075	1	5.6024	320.1562	21.1671	3.31 · 10⁻⁴
	(25 mg/kg)	0.1028	0.1735	0.0075	1	5.6024	320.1562	21.1671	3.31 · 10⁻⁴
HSCC1 (head and neck cancer cells)	Control	0.0444	3.3548	0.0198	-	-	23.6087	10.2691	9.5 · 10⁻²
	Treatment 1	0.0444	1.4969	0.0190	1	5.0006	38.9545	27.8009	1.2 · 10⁻³
	(1 mg/kg)	0.0444	1.4969	0.0190	1	5.0006	38.9545	27.8009	1.2 · 10⁻³
	Treatment 2	0.0444	1.4895	0.0190	1	6.0014	30.6914	27.8653	6.88 · 10⁻⁴
	(5 mg/kg)	0.0444	1.4895	0.0190	1	6.0014	30.6914	27.8653	6.88 · 10⁻⁴
	Treatment 3	0.0444	0.8864	0.0190	1	5.5002	46.0371	9.7061	7.65 · 10⁻⁵
	(25 mg/kg)	0.0444	0.8864	0.0190	1	5.5002	46.0371	9.7061	7.65 · 10⁻⁵

First-order optimality (FOO) is a measure of the closeness of the solution to the optimal

ISSN: 1745-6150